Original Research18 August 2015
A Cohort Study
    Author, Article, and Disclosure Information



    Ulcerative colitis (UC) can be treated with surgery or medications. Patients often must choose between long-term immunosuppressant therapy or total colectomy. Whether one of these treatment approaches has a mortality benefit is uncertain.


    To determine whether patients with advanced UC treated with elective colectomy have improved survival compared with those treated with medical therapy.


    Retrospective matched cohort study.


    Data from all 50 states for Medicaid beneficiaries (2000 to 2005), Medicare beneficiaries (2006 to 2011), and dual-eligible persons (2000 to 2011).


    830 patients with UC pursuing elective colectomy and 7541 matched patients with UC pursuing medical therapy.


    The primary outcome was time to death. Cox proportional hazards models were used to compare the survival of patients with advanced UC treated with elective colectomy or medical therapy. The models controlled for significant comorbid conditions through matched and adjusted analysis.


    The mortality rates associated with elective surgery and medical therapy were 34 and 54 deaths per 1000 person-years, respectively. Elective colectomy was associated with improved survival compared with long-term medical therapy (adjusted hazard ratio [HR], 0.67 [95% CI, 0.52 to 0.87]), although this result did not remain statistically significant in all sensitivity analyses. Post hoc analysis by age group showed improved survival with surgery in patients aged 50 years or older with advanced UC (HR, 0.60 [CI, 0.45 to 0.79]; P  = 0.032 for age-by-treatment interaction).


    Retrospective nonrandomized analysis is subject to residual confounding. The source cohort was derived from different databases throughout the study. Sensitivity and secondary analyses had reduced statistical power.


    Elective colectomy seemed to be associated with improved survival relative to medical therapy among patients aged 50 years or older with advanced UC.

    Primary Funding Source:

    National Institutes of Health and Agency for Healthcare Research and Quality.


    • 1. Harrell LEHanauer SBMesalamine derivatives in the treatment of Crohn's disease. Gastroenterol Clin North Am2004;33:303-17, ix-x. [PMID: 15177540] CrossrefMedlineGoogle Scholar
    • 2. Lichtenstein GRFeagan BGCohen RDSalzberg BADiamond RHChen DMet alSerious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol2006;4:621-30. [PMID: 16678077] CrossrefMedlineGoogle Scholar
    • 3. Toruner MLoftus EVHarmsen WSZinsmeister AROrenstein RSandborn WJet alRisk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology2008;134:929-36. [PMID: 18294633] doi:10.1053/j.gastro.2008.01.012 CrossrefMedlineGoogle Scholar
    • 4. Lewis JDGelfand JMTroxel ABForde KANewcomb CKim Het alImmunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol2008;103:1428-35. [PMID: 18494836] doi:10.1111/j.1572-0241.2008.01836.x CrossrefMedlineGoogle Scholar
    • 5. Rutgeerts PSandborn WJFeagan BGReinisch WOlson AJohanns Jet alInfliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med2005;353:2462-76. [PMID: 16339095] CrossrefMedlineGoogle Scholar
    • 6. Colombel JFLoftus EVTremaine WJEgan LJHarmsen WSSchleck CDet alThe safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology2004;126:19-31. [PMID: 14699483] CrossrefMedlineGoogle Scholar
    • 7. Colombel JFSandborn WJReinisch WMantzaris GJKornbluth ARachmilewitz Det alSONIC Study GroupInfliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med2010;362:1383-95. [PMID: 20393175] doi:10.1056/NEJMoa0904492 CrossrefMedlineGoogle Scholar
    • 8. Bongartz TSutton AJSweeting MJBuchan IMatteson ELMontori VAnti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA2006;295:2275-85. [PMID: 16705109] CrossrefMedlineGoogle Scholar
    • 9. Siegel CAMarden SMPersing SMLarson RJSands BERisk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol2009;7:874-81. [PMID: 19558997] doi:10.1016/j.cgh.2009.01.004 CrossrefMedlineGoogle Scholar
    • 10. Kandiel AFraser AGKorelitz BIBrensinger CLewis JDIncreased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut2005;54:1121-5. [PMID: 16009685] CrossrefMedlineGoogle Scholar
    • 11. Beigel FJürgens MTillack CSubklewe MMayr DGöke Bet alHepatosplenic T-cell lymphoma in a patient with Crohn's disease. Nat Rev Gastroenterol Hepatol2009;6:433-6. [PMID: 19575026] doi:10.1038/nrgastro.2009.87 CrossrefMedlineGoogle Scholar
    • 12. Mackey ACGreen LLeptak CAvigan MHepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update [Letter]. J Pediatr Gastroenterol Nutr2009;48:386-8. [PMID: 19274799] CrossrefMedlineGoogle Scholar
    • 13. Ochenrider MGPatterson DJAboulafia DMHepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk2010;10:144-8. [PMID: 20371449] doi:10.3816/CLML.2010.n.021 CrossrefMedlineGoogle Scholar
    • 14. Su CLewis JDGoldberg BBrensinger CLichtenstein GRA meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology2007;132:516-26. [PMID: 17258720] CrossrefMedlineGoogle Scholar
    • 15. Timmer AMcDonald JWTsoulis DJMacdonald JKAzathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev2012;9:CD000478. [PMID: 22972046] doi:10.1002/14651858.CD000478.pub3 CrossrefMedlineGoogle Scholar
    • 16. Kaplan GGMcCarthy EPAyanian JZKorzenik JHodin RSands BEImpact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology2008;134:680-7. [PMID: 18242604] doi:10.1053/j.gastro.2008.01.004 CrossrefMedlineGoogle Scholar
    • 17. Alves APanis YBouhnik YMaylin VLavergne-Slove AValleur PSubtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg2003;197:379-85. [PMID: 12946792] CrossrefMedlineGoogle Scholar
    • 18. Pal SSahni PPande GKAcharya SKChattopadhyay TKOutcome following emergency surgery for refractory severe ulcerative colitis in a tertiary care centre in India. BMC Gastroenterol2005;5:39. [PMID: 16316474] CrossrefMedlineGoogle Scholar
    • 19. Roberts SEWilliams JGYeates DGoldacre MJMortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ2007;335:1033. [PMID: 17977817] CrossrefMedlineGoogle Scholar
    • 20. Sagar PMPemberton JHIntraoperative, postoperative and reoperative problems with ileoanal pouches. Br J Surg2012;99:454-68. [PMID: 22307828] doi:10.1002/bjs.8697 CrossrefMedlineGoogle Scholar
    • 21. Michelassi FLee JRubin MFichera AKasza KKarrison Tet alLong-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg2003;238:433-41. [PMID: 14501509] CrossrefMedlineGoogle Scholar
    • 22. Fazio VWZiv YChurch JMOakley JRLavery ICMilsom JWet alIleal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg1995;222:120-7. [PMID: 7639579] CrossrefMedlineGoogle Scholar
    • 23. Bach SPMortensen NJIleal pouch surgery for ulcerative colitis. World J Gastroenterol2007;13:3288-300. [PMID: 17659667] CrossrefMedlineGoogle Scholar
    • 24. Nicholls RJClark DNKelso LCrowe AMKnight ADHodgkins Pet alNationwide linkage analysis in Scotland implicates age as the critical overall determinant of mortality in ulcerative colitis. Aliment Pharmacol Ther2010;31:1310-21. [PMID: 20236256] doi:10.1111/j.1365-2036.2010.04302.x CrossrefMedlineGoogle Scholar
    • 25. Bewtra MKilambi VFairchild AOSiegel CALewis JDJohnson FRPatient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis2014;20:103-14. [PMID: 24280881] doi:10.1097/01.MIB.0000437498.14804.50 CrossrefMedlineGoogle Scholar
    • 26. Arora GSingh GVadhavkar SShah SBMannalithara AMithal Aet alIncidence and risk of intestinal and extra-intestinal complications in Medicaid patients with inflammatory bowel disease: a 5-year population-based study. Dig Dis Sci2010;55:1689-95. [PMID: 20428948] doi:10.1007/s10620-010-1236-z CrossrefMedlineGoogle Scholar
    • 27. Osterman MTHaynes KDelzell EZhang JBewtra MBrensinger Cet alComparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin Gastroenterol Hepatol2014;12:811-817. [PMID: 23811254] doi:10.1016/j.cgh.2013.06.010 CrossrefMedlineGoogle Scholar
    • 28. Winthrop KLBaddley JWChen LLiu LGrijalva CGDelzell Eet alAssociation between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA2013;309:887-95. [PMID: 23462785] doi:10.1001/jama.2013.1099 CrossrefMedlineGoogle Scholar
    • 29. Gross RBilker WBStrom BLHennessy SValidity and comparison of two measures of days supply in Medicaid claims data. Pharmacoepidemiol Drug Saf2008;17:1029-32. [PMID: 18442181] doi:10.1002/pds.1606 CrossrefMedlineGoogle Scholar
    • 30. Hennessy SLeonard CEPalumbo CMNewcomb CBilker WBQuality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care2007;45:1216-20. [PMID: 18007173] CrossrefMedlineGoogle Scholar
    • 31. Bewtra MSu CLewis JDTrends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol2007;5:597-601. [PMID: 17382602] CrossrefMedlineGoogle Scholar
    • 32. Gagne JJGlynn RJAvorn JLevin RSchneeweiss SA combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol2011;64:749-59. [PMID: 21208778] doi:10.1016/j.jclinepi.2010.10.004 CrossrefMedlineGoogle Scholar
    • 33. Sato TMatsuyama YMarginal structural models as a tool for standardization. Epidemiology2003;14:680-6. [PMID: 14569183] CrossrefMedlineGoogle Scholar
    • 34. Scott FIVajravelu RKBewtra MMamtani RLee DGoldberg DSet alThe benefit-to-risk balance of combining infliximab with azathioprine varies with age: a Markov model. Clin Gastroenterol Hepatol2015;13:302-309. [PMID: 25117775] doi:10.1016/j.cgh.2014.07.058 CrossrefMedlineGoogle Scholar
    • 35. Lichtenstein GRCohen RFeagan BGSandborn WJSalzberg BChen Det alSafety of infliximab and other Crohn's disease therapies—TREAT registry data with nearly 24,575 patient years of follow up. Am J Gastroenterol2008;103:P14. CrossrefGoogle Scholar
    • 36. Bewtra MSiegel CALewis JDUlcerative colitis patients taking immunosuppressive medications report inadequate understanding of surgical options. Gastroenterology2012;142 Suppl 1 S794. CrossrefGoogle Scholar
    • 37. Waljee AKHiggins PDWaljee JFTujios SRSaxena ABrown LKet alPerceived and actual quality of life with ulcerative colitis: a comparison of medically and surgically treated patients. Am J Gastroenterol2011;106:794-9. [PMID: 21364547] doi:10.1038/ajg.2011.39 CrossrefMedlineGoogle Scholar
    • 38. McLeod RSBaxter NNQuality of life of patients with inflammatory bowel disease after surgery. World J Surg1998;22:375-81. [PMID: 9523520] CrossrefMedlineGoogle Scholar
    • 39. Davies RJO'Connor BIVictor CMacRae HMCohen ZMcLeod RSA prospective evaluation of sexual function and quality of life after ileal pouch-anal anastomosis. Dis Colon Rectum2008;51:1032-5. [PMID: 18454295] doi:10.1007/s10350-008-9248-x CrossrefMedlineGoogle Scholar
    • 40. Wexelman BAEden ERose KMSurvey of New York City resident physicians on cause-of-death reporting, 2010. Prev Chronic Dis2013;10:E76. [PMID: 23660118] doi:10.5888/pcd10.120288 CrossrefMedlineGoogle Scholar
    • 41. Ravakhah KDeath certificates are not reliable: revivification of the autopsy. South Med J2006;99:728-33. [PMID: 16866055] CrossrefMedlineGoogle Scholar
    • 42. Ananthakrishnan ANEnvironmental triggers for inflammatory bowel disease. Curr Gastroenterol Rep2013;15:302. [PMID: 23250702] doi:10.1007/s11894-012-0302-4 CrossrefMedlineGoogle Scholar